secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001213900-23-001162
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics engages director Paul Kelly as special advisor at $32k/mo; Kelly loses independent director status
--------------------------------------------------------------------------------

- Paul Kelly, a director, entered Advisory Agreement as Special Advisor to CEO effective Jan 1, 2023, with $32,000 monthly fee.
- Kelly will no longer be considered independent director; he resigns from Audit and Compensation Committees.
- Charles J. Casamento appointed Chairman of Compensation Committee effective Jan 1, 2023.
- Agreement term of one year, renewable automatically; early termination with 30 days' notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023001162/0001213900-23-001162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023001162/ea171314-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-001162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer